UNSPSC 51313427: Dexbrompheniramine tannate

This classification denotes the tannate form of a histamine-1 receptor antagonist with the molecular formula C16H19BrN2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 75T64B71RP, chemically known as 3-(4-bromophenyl)-n,n-dimethyl-3-pyridin-2-yl-propan-1-amine but more generally known as dexbrompheniramine, which bears US NIH Compound Identifier 16960. European Medicines Agency schedules Dexbrompheniramine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07021MIG.

UNSPSC 51313427 Dexbrompheniramine tannate is a Commodity code that captures pharmaceutical products procured by state and local health agencies, but the recent state and local opportunities tagged under this code show little relevance to dexbrompheniramine tannate specifically. Instead, the opportunities reflect broader pharmacy benefit and emergency health-supply procurement: Seminole County, Florida is soliciting naloxone and drug deactivation systems through an IFB; the Texas Health and Human Services Commission posted a Request for Information on direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) released an RFP for generic multi-source pharmaceuticals and over-the-counter products through authorized wholesalers. The mismatch between the code's nominal scope and the actual work being solicited suggests this Commodity code does not align with current state and local procurement patterns for this specific drug product.

Geographic activity centers on Florida, Texas, and Minnesota based on the recent opportunities. Issuing bodies include county health departments (Seminole County), state health agencies (Texas HHS Commission), and cooperative purchasing vehicles spanning multiple states (MMCAP, which serves participating states including Oregon). The Seminole County IFB closes July 26, 2023, and requires quarterly deliveries of naloxone and deactivation systems; the Texas RFI closed April 3, 2026, to gather vendor capacity for direct-to-manufacturer prescription fulfillment; and MMCAP's RFP for generic pharmaceuticals and OTC products closed March 26, 2026, with contract effectiveness targeted for July 1, 2026. No recent opportunities directly solicit dexbrompheniramine tannate products, indicating minimal current state and local demand under this specific code classification.